Leidos: A Defense-Tech Re-Rating With a VBA Air Pocket
The quarter was strong, the 2027 warning was explicit, and the stock has already voted.
LDOS · Earnings Call · 2026-11-03
The quarter the market wanted — and the guidance it didn't
Leidos printed a clean Q3: revenue of $4.63 billion, up 4% total and 1% organic; adjusted EBITDA of $644 million at a 13.9% margin; non-GAAP EPS of $3.62, up 19%; and free cash flow of $476 million. Year-to-date free cash flow hit $1.5 billion, already above the original full-year target. Book-to-bill was 1.2x, total backlog reached $49.6 billion, up 4%, and funded backlog rose 22% to $11.1 billion. CEO Tom Bell did not bury the lede: “Revenue grew 4%. Adjusted EBITDA improved to 13.9%. Non-GAAP diluted EPS increased 19% year-over-year...” — Thomas Bell, Chief Executive Officer · 2026-11-03. On the last filed quarter, revenue was $4.6 billion, so the call was an acceleration, not a rescue.
But the stock had already run 34% in the last 90 trading days, per the tape, and sits within 8% of its recent high. That matters. This was not a beat that surprised the market; it was a beat that confirmed a re-rating already underway. The market is no longer pricing Leidos as a pure VBA contractor. It is pricing a defense-tech and energy-infrastructure story with a contract overhang attached. The tension is that management spent much of the call telling investors the overhang still matters.
VBA: from fog to a structured option
The biggest change this quarter was not the P&L; it was the shape of the VBA recompete. After months of waiting, Leidos now has a draft RFP, with a final RFP expected later this month. The current domestic contract is likely to be extended through the first half of 2027, and the customer's planned new-contract start is July 1, 2027. A decision is expected around April or May 2027. Tom Bell was explicit that the range of outcomes cannot yet be bounded: “the boundary conditions aren't going to be able to be articulated until the second quarter of this year, probably halfway through '27” — Thomas Bell, Chief Executive Officer · 2026-11-03.
What is new is the architecture. The draft envisions six service groups, each an IDIQ with two to four vendors; two vendors per group must be able to stand up capability within 30 days, and the draft rewards the best performers with disproportionate work share. That is a very different animal from a simple four-region, four-vendor recompete. It creates a path where Leidos could lose volume, but it also creates a path where Leidos could gain share. CFO Chris Cage framed the upside: “there is an upside case that Leidos comes out of this with more work share than we have today” — Chris Cage, Chief Financial Officer · 2026-11-03.
This has been the company's central anxiety for at least three quarters. In August, Bell called the fourth quarter a “good jumping off point for what we're looking at for 2027” — Thomas Bell, Chief Executive Officer · 2026-08-04, and Cage said “job 1 is to resecure this franchise” — Chris Cage, Chief Financial Officer · 2026-08-04. In May, Bell said it was “becoming difficult to imagine a seismic shift in how we serve veterans” — Thomas Bell, Chief Executive Officer · 2026-05-05. Back in November 2025, Cage warned that “next year is a year that it'd be difficult to add to the capacity that we're seeing right now given that fourth vendor” — Chris Cage, Chief Financial Officer · 2025-11-04. So the VBA issue is not new. What is new is the explicit 2027 EPS warning.
it's clear that '27 is not a bottom line growth year for the company. It's accelerating top line growth in other parts of the portfolio.
That is the sentence the market has to reconcile with a 34% rally. The answer is that the rest of Leidos is growing fast enough to make the VBA look like a contained problem. Excluding Health, revenue grew 9% and non-GAAP operating income grew 48%. The company is effectively asking investors to value an absent Health Leidos — or at least a smaller, reset Health business — while the other segments carry the growth.
Defense Tech: the 'mature disruptor' gets a tape
Defense was the star. Book-to-bill was 1.9x in the quarter and 2.0x year-to-date. Leidos has booked more than $10 billion of Defense Tech awards over the last 18 months, including $6 billion year-to-date. More than a dozen programs are moving from development into rate production. IFPC has tripled in revenue and is on pace for full-rate potential in 2027. The company sees a path to a $1 billion munitions business by 2030, with Havoc Spear, the sea-launched nuclear-armed cruise missile, and counter-UAS as the anchors. Bell's new phrase is that Leidos is a mature disruptor — not a PowerPoint defense startup, but a scaled integrator that can also move fast.
That framing is company-unique, but the demand signal is not. The global tape over the last 30 days has been voting on Missile Defense Agency exposure, solid rocket motor suppliers, and space-based interceptor names. Defense reporters this week — LHX, GD, HWM, BWXT, DRS — are all talking about missile solutions, land systems, defense sales, component manufacturing, and counter-drone work. Leidos is riding a broad wave. The difference is that its Counter UAS capability is wrapped in a portfolio that also includes cyber, energy, and health, so the market has to decide whether to value it as a prime or as a collection of options.
The commercial push is the other new leg. Leidos is talking about repeatable commercial offerings such as Parcata, an AI-powered vulnerability detection and patching platform, and MySTR, a health-record product launched ahead of the President's September executive order on veterans' benefits. These are small today, but they are the first credible evidence that Leidos can sell productized software rather than only services. That is a different multiple if it scales.
Energy, tax, and the sum-of-the-parts argument
The Energy business is the quiet re-rating engine. Entrust is now integrated, the pipeline has grown 230% since the acquisition, and Leidos has more than $10 billion of orders targeted. Management tied the opportunity directly to data-center power demand and grid modernization. That is the same global theme showing up in data-center, utility, and electrical-equipment calls across the market. It is also why the Homeland segment grew 32% total and 15% organically.
Tax is the other tailwind. The Q3 non-GAAP effective tax rate was 15.1%, helped by state-tax pickups and a new research-credit calculation accepted by the IRS. Management called the research-credit change structural, though the impact will be more modest in out-years. That matters because it flatters EPS and cash flow without requiring revenue growth. Free cash flow was $476 million in the quarter, a 105% quarterly FCF yield, and 121% over the trailing 12 months.
The balance sheet is the constraint. Effective net cash was -$5.2 billion at the last filing, and gross leverage was 2.5x at quarter-end. Leidos bought back $500 million of stock in Q3 and raised the dividend by $0.02, consistent with Bell's view that the shares trade below intrinsic value. The valuation supports that argument: price to net income was 9.3x, and price to free cash flow was 6.3x. Those are not heroic multiples for a defense-tech franchise with a growing energy arm.
What to watch
The next catalysts are specific: the final VBA RFP this month, a decision around April/May 2027, fourth-quarter Health margins in the high teens, and formal 2027 guidance in February. Management also flagged that customer procurement activity is accelerating, with a next-12-month pipeline up 15% and $28 billion awaiting decision. If Defense Tech and Energy keep compounding, the sum-of-the-parts case can win even with a smaller VBA. If the VBA decision goes badly, the 2027 EPS air pocket is real and the stock's recent rally will look premature.
The quarter did not resolve Leidos. It sharpened the bet: a cheap, cash-generative defense-tech integrator with a contract overhang that is now finally visible. The market has started to look through the overhang. Management is still telling investors not to look too far.